IVD Definition and Classification in Myanmar

1. Key takeaways

In Section 1 of the Technical Guideline for Online Submission of Medical Devices, Myanmar sets out a definition of in vitro diagnostic (IVD) medical devices that is separate from the general device definition. An IVD is any reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment or system, whether used alone or in combination, intended by the product owner to be used for in vitro examination of any specimen derived from the human body, including blood and tissue donations, with the sole or principal purpose of providing three categories of information.

• The IVD definition and the general device definition exist side by side, and Section 2 of the guideline states that the general device risk classification rules apply to devices other than IVD medical devices, so IVDs follow a separate set of classification rules.
• When preparing IVD registration documents, companies must confirm that the IVD classification rules are the ones being applied.
• The classification essentials can be recorded as: 1 separate definition, 3 categories of information purposes, and 2 sets of classification rules.
• The definition expressly includes specimens receptacles, which pulls ordinary consumables such as blood collection tubes and sample cups into the IVD scope.
• The examination covers any specimen derived from the human body, expressly including blood and tissue donations, so donor screening assays fall squarely within the definition.
• Because the purpose clause is drafted around information provision rather than treatment, products that only support treatment monitoring must be assessed against the third information category rather than assumed to fall outside the scope.

2. Legal basis

The table below reproduces the IVD definitional framework from the FDA technical guideline, which operates as the operative administrative source in the absence of a dedicated device statute.

3. Expert insights

Insight 1: a separate IVD definition shows that Myanmar applies an independent regulatory logic to diagnostic products. This is consistent with the AMDD and with the practice of other ASEAN markets. Companies preparing IVD documentation must not apply the technical documentation template for general devices.

Insight 2: the classification rules are expressly divided into two sets. The heading of Section 2 of the guideline reads Risk Classification for General Medical Devices (Other than In-Vitro Diagnostic Medical Devices), and the reference list of the guideline cites the risk classification rules for IVD medical devices. This confirms that IVDs have an independent classification pathway. In practical terms this means the class assigned to an IVD under the IVD rules cannot be inferred from any general device rule table, and an assessment that mixes the two rule sets is likely to be challenged during review.

Insight 3: the inclusion of specimens receptacles widens the boundary of the device scope. The closing words of the provision, includes a specimens receptacle, expressly bring specimen containers within the IVD category. Consumables that appear ordinary, such as blood collection tubes and sample cups, are IVD medical devices in Myanmar. This is the category most easily missed in product lists, and an undeclared specimens receptacle discovered at review can force the entire portfolio list to be revised and resubmitted.

Insight 4: the purpose clause emphasises the sole or principal purpose, leaving room for judgement on multifunctional products. For products with both diagnostic and non-diagnostic uses, the classification must be determined according to the principal purpose, documented in writing before the registration pathway is fixed.

Insight 5: the IVD definition is structurally symmetrical with the general device definition. Both follow a three-part structure of scope of articles, intended use, and exclusion or limitation, which allows companies to build a single decision process for both. The symmetry argument is a practical estimate pending verification against the FDA’s current review practice.

4. Practical recommendations

• Do not apply the general device template to IVD documentation. Organise the materials according to the separate IVD definition and classification rules.
• Bring specimen containers into device list management. Blood collection tubes, sample cups and similar items must be declared together with the rest of the portfolio.
• Determine the principal purpose first for multifunctional products. Form a written conclusion before fixing the registration pathway.
• State the in vitro use limitation clearly in the instructions for use. Keep the wording consistent with the in vitro examination formulation in the definition.
• Retain an explanation of the applicable classification rules. Record in the technical documentation which rule set was used and the reasoning for the determination.

5. Verification checklist

• □ Confirmed that Myanmar has set out a separate definition for IVDs
• □ Confirmed that IVDs follow classification rules different from those for general devices
• □ Checked the IVD scope of articles (reagents, calibrators, control materials, instruments, systems)
• □ Confirmed that the definition includes specimens receptacles
• □ Organised the registration documents according to the IVD rules
• □ Brought specimen container products into the device list
• □ Recorded the reasoning for the applicable classification rules in the technical documentation

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com